TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03306472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase Inhibitor
Study: NCT02089009

Intervention type: OTHER
Group type: OTHER
Intervention: Retinal imaging
Description: Retinal imaging by using non-mydriatic camera devices
Study: NCT01255293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1000 centistoke silicone oil
Description: Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
Study: NCT02089009

Intervention type: OTHER
Group type: OTHER
Intervention: Retinal imaging
Description: Retinal imaging by using non-mydriatic camera devices

Intervention type: OTHER
Group type: OTHER
Intervention: Vessel measurements
Description: Vessel measurements based on the taken images by the use of a specialized software

Intervention type: OTHER
Group type: OTHER
Intervention: Vessel measurements
Description: Vessel measurements based on the taken images by the use of a specialized software

Intervention type: OTHER
Group type: OTHER
Intervention: Change in vessel diameters
Description: Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software

Intervention type: OTHER
Group type: OTHER
Intervention: Change in vessel diameters
Description: Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
Study: NCT03703232

Intervention type: DEVICE
Group type: OTHER
Intervention: Investigational prosthetic foot
Description: Individuals will complete 2-4 weeks of community walking with the investigational foot and compare to their regular prosthetic foot.
Study: NCT03061877

Intervention type: OTHER
Intervention: Anxiety or depression
Description: The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
Study: NCT02387242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single oral dose of rifampicin
Study: NCT02554786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate/Mometasone furoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate/Mometasone furoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol xinafoate/fluticasone propionate
Study: NCT02901522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry (baseline)
Description: Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry (baseline)
Description: Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry (20 - 22weeks)
Description: Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry (20 - 22weeks)
Description: Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: The general practioner received phone call to asthma care.
Study: NCT03853161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vapotherm
Description: A form of non invasive ventilation used in newborns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: A form of non invasive ventilation used in newborns
Study: NCT04705675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding Education
Description: The mothers were asked to remember the pseudonyms they used on the pretest and to use the same pseudonym on the posttest. Following the pretest, the mothers in the study group were taken into a separate room at the FHC and asked to breastfeed their infants. The mothers' breastfeeding behaviors were observed. After the breastfeeding, each mother was provided an average 30-minute session of individual education. All of the mothers in the study group received the education from the same researcher. Both audio and visual materials were used in the mothers' training.
Study: NCT03822234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified ileal conduit
Description: Modified ileal conduit (Extraperitonealization)
Study: NCT02148185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303
Study: NCT03631238

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling for total cholesterol and homocysteine and cognitive assessment by psychometric tests.
Description: all participant are subjected to cognitive assessment by psychometric tests by using the arabic version of Mini Mental State Exam (MMSE) and Memory Assessment Scale (MAS).~Blood samples were collected in the morning using 10 mL yellow top (plain) Vacutainer tubes.~Lipid profile (triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) were measured by Assiut university labs using Cholesterol Kits and analyzed by COBAS Integra analyzer.~Total cholesterol levels were calculated using the sum of the LDL and HDL plus one-fifth of triglyceride levels.~Samples of serum homocysteine are collected, centrifuged to separate plasma within 30 minutes after venipuncture and stored in specialized container in the Department of Clinical Pathology at (-20◦C) temperature.~Total homocysteine was measured by ELISA technique, Sinogen kits (Research Use Only) and Statfax-2100 microplate analyzer.
Study: NCT02773524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
Study: NCT02828618

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDS (Primary Debulkdung Surgery)
Description: PDS with maximum effort to achieve the goal of complete gross resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6 cycles of standard chemotherapy
Description: 6 cycles of standard chemotherapy after Primary Debuling Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Timing of surgery after 3 cycles of standard NACT, IDS
Description: Timing of surgery after 3 cycles of standard NACT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IDS
Description: IDS with maximum effort to achieve the goal of complete gross resection after NACT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 cycles of standard chemotherapy
Description: 3 more cycles (for a total of 6) of standard chemotherapy after IDS
Study: NCT01571570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg capsule
Description: single oral dose of 150 mg TMC435 150 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg capsule
Description: single oral dose of 150 mg TMC435 150 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg capsule
Description: single oral dose of 150 mg TMC435 150 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg oral suspension (20 mg/mL)
Description: single oral dose of 150 mg TMC435 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg oral suspension (20 mg/mL)
Description: single oral dose of 150 mg TMC435 oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg oral solution (10 mg/mL)
Description: single oral dose of 150 mg TMC435 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg oral solution (10 mg/mL)
Description: single oral dose of 150 mg TMC435 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg capsule concept K
Description: single oral dose of 150 mg TMC435 capsule concept K

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 150 mg capsule concept L
Description: single oral dose of 150 mg TMC435 capsule concept L
Study: NCT02885636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: : Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Saline inhaled through a nebulizer as a single dose
Study: NCT03434587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Syndactyly
Description: Syndactyly

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduction and inmobilization
Description: Closed reduction and inmobilization with splint
Study: NCT01255293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 5000 centistoke silicone oil
Description: Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
Study: NCT04163367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer Kids
Description: A behaviorally based parent training program with the purpose to reduce or prevent child abuse.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention as usual (IAU)
Description: Everything that's included in the social service units' regular handling of cases; such as the formal investigation and family treatment. The units cannot offer Safer Kids as a part of IAU.
Study: NCT01830205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study: NCT04146116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal povidone-iodine
Description: povidone-iodine USP, 10% w/w antiseptic
Study: NCT02923986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 (varying dose)
Description: BP1001 (varying dose)
Study: NCT00665340

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5m, 10 mg and 20 mg 1 h prior to sexual intercourse
Study: NCT01150916

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BNP, SAAG, ascites total protein, echocardiography
Description: diagnostic tests
Study: NCT02923986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1001 (fixed dose)
Description: BP1001 (fixed dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib
Study: NCT01525264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIM-CHI
Description: The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
Study: NCT01150916

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BNP, SAAG, ascites total protein, echocardiography
Description: diagnostic tests

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BNP, SAAG, ascites total protein, echocardiography
Description: diagnostic tests

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BNP, SAAG, ascites total protein, echocardiography
Description: diagnostic tests
Study: NCT02172872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard combination chemotherapy
Description: 1. Cycle 1~   1. daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~2. Cycle 2~   1. daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~3. Cycle 3 (mini-ICE)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days~4. Cycle 4 (mini-ICE) (optional)~   1. idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~  2. cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~  3. etoposide (100 mg/m²) infusion (1 hr) for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: 1. Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days~2. Cycle 2~   1. if bone marrow (BM) blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~3. Cycle 3~   1. if BM blasts \< 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~  2. if BM blasts \>= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~4. Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days~5. Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days~Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available.
Study: NCT00448669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT01525264

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Wife Control Group
Description: Intervention group of couples who received education about importance of Healthy diet
Study: NCT00252239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenecteplase
Description: This study will compare 3 different doses of tenecteplase to tPA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator, tPA
Description: To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
Study: NCT01687478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Administered Orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine
Description: Administered Orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally
Study: NCT01751932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM Monitoring
Description: All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
Study: NCT02511821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Complete online surveys

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivofit watch
Description: Wear Vivofit watch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03213730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D-MOT Neurotracker
Description: A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Attention Intervention
Description: The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
Study: NCT00654758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M200 (Volociximab), Carboplatin, Paclitaxel
Description: Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
Study: NCT01898650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR scan
Study: NCT00117325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: Aqueous Nasal Spray 100mcg
Study: NCT04257045

Intervention type: OTHER
Intervention: Interview
Description: Participate in semi-structure, in-depth qualitative interviews
Study: NCT04287985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose-Placebo
Description: Unit Dose Strength - 0.9%.
Study: NCT01002222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS-2
Description: 15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
Study: NCT01998776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 200ug four times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Starch four times daily
Study: NCT04257045

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT02802631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocin (minocycline) for Injection
Description: Intravenous formulation of minocycline, a derivative of tetracycline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - Normal Saline
Study: NCT03796039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Description: Standing for an additional 100 minutes per week; 20 minutes Monday-Friday
Study: NCT04598048

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Patients will complete an EQ-5D questionnaire, medication and lifestyle questions
Study: NCT03427593

Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: FACS analyses
Description: FACS analyses

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: FACS analyses
Description: FACS analyses

Intervention type: GENETIC
Group type: OTHER
Intervention: FACS analyses
Description: FACS analyses

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Target Sequencing by NGS ( Next-generation sequencing)
Description: Target Sequencing by NGS ( Next-generation sequencing)

Intervention type: GENETIC
Group type: OTHER
Intervention: Target Sequencing by NGS ( Next-generation sequencing)
Description: Target Sequencing by NGS ( Next-generation sequencing)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole Exome Sequencing
Description: Whole Exome Sequencing

Intervention type: GENETIC
Group type: OTHER
Intervention: Whole Exome Sequencing
Description: Whole Exome Sequencing
Study: NCT04005469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
Study: NCT02729116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitafloxacin
Description: Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Patients are given IV ertapenem for 14 days
Study: NCT02782234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contract management